dm+d

420261000

Articles

Vaccination and antibiotic prescribing in patients with asplenia or splenic dysfunction in primary care

24 April 2019Following the death of a young asplenic patient in 2016 our project involves the identification and review of asplenic or hyposplenic patients in primary care,…
Search Articles

Refrigerated Storage

MenveoGSK

GSK
Menveo
Powder and solution for solution for injection in a vial

In the event of an inadvertent temperature excursion the following data may be used:
A maximum cumulative time of 120 hours is permitted for the vaccine vials to be stored at temperatures above 8°C through 25°C
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
Contact GSK in cases where the product has been exposed to temperature deviation other than described above. Refer to the current BNF for company contact details.

No, if exposed to conditions as described above
Yes, if exposed to conditions described above
19 December 2019
London Medicines Information Service

NimenrixPfizer limited

Pfizer limited
Nimenrix
Powder and solvent for solution for injection in pre-filled syringe and ampoules

Contact Pfizer in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.

3 August 2020
London Medicines Information Service

New Medicines

MenQuadfiMeningitis ACYW prevention in toddlers and above

Information

MenQuadfi
Vaccine
Sanofi
Sanofi

Development and Regulatory status

Launched
Licensed but not launched
Licensed but not launched
September 2021
Sep 21Available in the UK, Price 1x1 solution for injection vial = £31.50 [10,11].
Nov 20Company plans to make MenQuadfi available in several European countries from 2021 to help protect individuals 12 months of age and older. Phase 3 studies are ongoing to investigate the vaccine in infants from 6 weeks of age [9].
Nov 20The EC has approved MenQuadfi [8].
Sep 20Recommended for EU approval by CHMP - the full indication is "for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y. The use of this vaccine should be in accordance with official recommendations" [7].
Apr 20Approved in US [6].
Oct 19Filed in EU via centralised procedure [5].
Jul 19Is now pre-registration in the US for use in children aged 2 years and over; EU filings for use in children aged 12 months and older remain planned for 2019 [4].
Feb 19EU submission expected 2019 [1].

Category

A quadrivalent meningococcal polysaccharide vaccine, conjugated to tetanus toxoid
UK cases of meningococcal meningitis occur mostly in younger people, and fatality rates have fallen in recent years due to the introduction of vaccination programmes covering infants and older children; annual incidence of invasive disease reported in 2012 was 2 per 100,000 [3].
Meningitis ACYW prevention in toddlers and above
Intramuscular

Trial or other data

Mar 19PIII trials show efficacy alone, and a series of further PIII trials is in progress to confirm efficacy when given concurrently with other paediatric vaccines (NCT03547271, NCT03691610, NCT03673462, NCT03537508) [2].